HIV-associated lymphoma.
Kaplan
L D
LD
University of California, San Francisco, USA.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D011878:Radiotherapy
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents